AASK COHORT STUDY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 非裔美国人肾脏病和高血压研究（AASK）队列研究是一项前瞻性观察性研究，将是AASK临床试验的发展。 AASK试验是一项随机试验，测试了用作一线抗高血压治疗的3种不同药物（雷米普利、美托洛尔和曲马多）和2种水平的血压控制（常规控制和更积极的控制）对肾功能（肾小球滤过率和临床肾脏事件）的影响。 在4-6年前随机进入AASK试验的1，094名参与者中，我们预计有650-750名未达到终末期肾病（ESRD）的个体将参加AASK队列研究。 此外，将要求在AASK试验期间达到ESRD的个体参加一次访视，以采集脱氧核糖核酸（DNA）。 AASK队列受试者每年将接受2次数据收集访视，最多4次额外的血压管理访视。 要监测的暴露包括环境、遗传、生理和社会经济因素。 主要肾脏结局将是定义为血清肌酐加倍、达到ESRD或死亡的临床结局。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The African American Study of Kidney Disease and Hypertension (AASK) Cohort Study is a prospective, observational study that will be a development from the AASK clinical trial. The AASK trial was a randomized trial that tested the effect on kidney function (glomerular filtration rate and clinical kidney events) of 3 different medications used as first line antihypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of blood pressure control (usual control and more aggressive control). Of the 1,094 participants randomized into the AASK trial 4-6 years ago, we anticipate that 650-750 individuals who have not reached end-stage renal disease (ESRD) will enroll in the AASK Cohort study. In addition, those individuals who reached ESRD during the AASK trial will be asked to participate for one visit for collection of deoxyribonucleic acid (DNA). The AASK Cohort participants will have 2 data collection visits each year and up to 4 additional visits for blood pressure management. Exposures to be monitored include environmental, genetic, physiologic, and socio-economic factors. The primary renal outcome will be a clinical outcome defined by doubling of serum creatinine, attainment of ESRD, or death.